Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Recent Advances in Diagnosis and Treatment of Alzheimer's Disease

알츠하이머병의 최신지견

  • Lee, Jung Jae (Department of Psychiatry, College of Medicine, Dankook University) ;
  • Lee, Seok Bum (Department of Psychiatry, College of Medicine, Dankook University)
  • 이정재 (단국대학교 의과대학 정신건강의학교실) ;
  • 이석범 (단국대학교 의과대학 정신건강의학교실)
  • Received : 2016.04.19
  • Accepted : 2016.05.17
  • Published : 2016.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder in which neuronal loss causes cognitive decline and other neuropsychiatric problems. It can be diagnosed based on history, examination, and appropriate objective assessments, using standard criteria such as the Diagnostic and Statistical Manual of Mental Disorders or the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA). Brain imaging and biomarkers are making progress in the differential diagnoses among the different disorders. The cholinesterase inhibitors, donepezil, rivastigmine and galantamine and N-methyl-D-aspartate receptors antagonist memantine are approved by the US Food and Drug Administration for AD. Recently some acetylcholinesterase inhibitors gained approval for the treatment of severe AD and became available in a higher dose formulation or a patch formulation. Optimal care in AD is multifactorial and it should include early diagnosis and multidisciplinary care with pharmacological and nonpharmacological interventions including exercise interventions, cognitive interventions and maintenance of social networks.

Keywords

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association;2013.
  2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269. https://doi.org/10.1016/j.jalz.2011.03.005
  3. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279. https://doi.org/10.1016/j.jalz.2011.03.008
  4. Kwon JS, Kim J, Namkoong K, Bahk W, Shin M, Yu B, et al. Diagnostic and statistical manual of mental disorders, 5th edition. Seoul: Hakjisa;2015.
  5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944. https://doi.org/10.1212/WNL.34.7.939
  6. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 2005;380:127-132. https://doi.org/10.1016/j.neulet.2005.01.031
  7. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;80 Spec No 2:S160-S167. https://doi.org/10.1259/bjr/97295129
  8. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412-419. https://doi.org/10.1126/science.278.5337.412
  9. Wakabayashi K, Narisawa-Saito M, Iwakura Y, Arai T, Ikeda K, Takahashi H, et al. Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease. Neurobiol Aging 1999;20:287-295. https://doi.org/10.1016/S0197-4580(99)00035-4
  10. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-1065. https://doi.org/10.1016/S0140-6736(06)68350-5
  11. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32:1234-1251. https://doi.org/10.1016/j.clinthera.2010.06.019
  12. Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol 2011;11:57. https://doi.org/10.1186/1471-2377-11-57
  13. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther 2013;19:745-752.
  14. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frolich L, Hock C, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009;8:39-47. https://doi.org/10.1016/S1474-4422(08)70261-8
  15. Grossberg GT, Manes F, Allegri RF, Gutierrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 2013;27:469-478. https://doi.org/10.1007/s40263-013-0077-7
  16. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324. https://doi.org/10.1001/jama.291.3.317
  17. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-89. https://doi.org/10.2174/156720508783884576
  18. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:893-903. https://doi.org/10.1056/NEJMoa1106668
  19. Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer's disease. Lancet 23 2016 Feb [Epub ahead of print]. http://dx.doi.org/10.1016/S0140-6736(15)01124-1.
  20. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311-321. https://doi.org/10.1056/NEJMoa1312889
  21. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115-9129. https://doi.org/10.1523/JNEUROSCI.2361-07.2007
  22. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011;118:658-667. https://doi.org/10.1111/j.1471-4159.2011.07337.x
  23. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010;30:16559-16566. https://doi.org/10.1523/JNEUROSCI.4363-10.2010
  24. Beason-Held LL, Moghekar A, Zonderman AB, Kraut MA, Resnick SM. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke 2007;38:1766-1773. https://doi.org/10.1161/STROKEAHA.106.477109
  25. Kirk-Sanchez NJ, McGough EL. Physical exercise and cognitive performance in the elderly: current perspectives. Clin Interv Aging 2014;9:51-62.
  26. Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review. Int Psychogeriatr 2014;26:9-18.
  27. Arkin S. Language-enriched exercise plus socialization slows cognitive decline in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2007;22:62-77. https://doi.org/10.1177/1533317506295377
  28. Aguirre E, Woods RT, Spector A, Orrell M. Cognitive stimulation for dementia: a systematic review of the evidence of effectiveness from randomised controlled trials. Ageing Res Rev 2013;12:253-262. https://doi.org/10.1016/j.arr.2012.07.001
  29. NICE. Dementia: supporting people with dementia and their carers in health and social care [Internet]. UK: NICE; 2006 [updated 2016 May]. Available from: https://www.nice.org.uk/guidance/cg42.
  30. Fratiglioni L, Wang HX, Ericsson K, Maytan M, Winblad B. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet 2000;355:1315-1319. https://doi.org/10.1016/S0140-6736(00)02113-9
  31. Miranda-Castillo C, Woods B, Galboda K, Oomman S, Olojugba C, Orrell M. Unmet needs, quality of life and support networks of people with dementia living at home. Health Qual Life Outcomes 2010;8:132. https://doi.org/10.1186/1477-7525-8-132
  32. Logsdon RG, McCurry SM, Teri L. Evidence-Based Interventions to Improve Quality of Life for Individuals with Dementia. Alzheimers Care Today 2007;8:309-318.
  33. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci 1997;52:M369-M377.